Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models Post author:andrewkaretas Post published:August 23, 2023 Post category:BCMA/Scientific Publications Continue ReadingConstitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models
August 2, 2023 5:00 PM EDT : Allogene Therapeutics Second Quarter 2023 Conference Call Post author:andrewkaretas Post published:July 26, 2023 Post category:Events Continue ReadingAugust 2, 2023 5:00 PM EDT : Allogene Therapeutics Second Quarter 2023 Conference Call
Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 15, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 13, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 12, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Presentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 9, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
June 9, 2023 12:45 PM EDT : Jefferies Healthcare Conference Post author:andrewkaretas Post published:May 30, 2023 Post category:Events Continue ReadingJune 9, 2023 12:45 PM EDT : Jefferies Healthcare Conference
June 14, 2023 4:20 PM EDT : Global Healthcare Conference Post author:andrewkaretas Post published:May 30, 2023 Post category:Events Continue ReadingJune 14, 2023 4:20 PM EDT : Global Healthcare Conference
May 30, 2023 9:30 AM EDT : TD Cowen 4th Annual Oncology Innovation Summit Post author:andrewkaretas Post published:May 30, 2023 Post category:Events Continue ReadingMay 30, 2023 9:30 AM EDT : TD Cowen 4th Annual Oncology Innovation Summit
The CAR T Revolution Continues: Progress Against Solid Tumors Post author:andrewkaretas Post published:May 2, 2023 Post category:Perspectives Continue ReadingThe CAR T Revolution Continues: Progress Against Solid Tumors
